drugset / Trial / NCT07623824

A Phase III Clinical Trial to Evaluate the Efficacy and Safety of Octreotide Long-acting Injection in Patients With Acromegaly

NCT07623824

Phase 3 Not yet recruiting 154 enrolled CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

he purpose of this study is to evaluate the efficacy and safety of SYHX2008 injection in in patients with acromegaly.

Timeline

Start
2026-05-31
Primary completion
2029-07-31
Completion
2029-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Octreotide Peptide Intramuscular
Subject SYHX2008 Unknown Subcutaneous

Indications